Augurex Life Sciences Corp.
Paul Terry serves as CEO of Photonic Inc. since October 2019, focusing on quantum computing, quantum internet, and quantum AI. In addition, Paul is President of NewOak and has held various board positions, including member of the Board at Augurex Life Sciences Corp. and Genome British Columbia, where Paul chaired the Entrepreneurship and Commercialisation Subcommittee. Previous leadership roles include CTO and CEO at PHEMI, Partner at Magellan Angel Partners, and Adjunct Professor at Simon Fraser University, specializing in MBA courses related to new product development and innovation. Paul's extensive education includes an MBA from Cranfield School of Management, a PhD in Electrical Engineering from the University of Liverpool, and various marketing and corporate director qualifications.
This person is not in the org chart
This person is not in any teams
Augurex Life Sciences Corp.
Augurex is a biotechnology company that is transforming health management and improving patient outcomes through biomarker blood tests. Augurex’s first commercialized blood test, the 14-3-3η Blood Test, can detect Rheumatoid Arthritis earlier, show treatment effectiveness, and reveal joint damage.